查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1108545

全身麻醉劑的全球市場 - 各藥物類型，各給藥途徑，各手術類型，各終端用戶:機會分析與產業預測(2021年～2031年)

General Anesthesia Drugs Market By TYPE OF DRUGS, By ROUTE OF ADMNISTRATION, By SURGERY TYPE, By END USER : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 284 Pages | 商品交期: 2-3個工作天內

價格

全球全身麻醉劑的市場規模，從2021年的54億50萬美元到2031年達到77億3,630萬美元，2022年～2031年預計以3.5％的年複合成長率成長。

主要由於髖關節和膝關節的置換手術，心血管手術，一般外科手術，癌症手術等手術增加，老年人口的擴大，骨關節炎和神經疾病的流行，牽引市場。

本報告提供全球全身麻醉劑市場相關調查分析，市場市場趨勢，市場區隔分析，地區分析，企業形勢等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
    • 主要的投資口袋
  • 波特的五力分析
  • 主要企業的定位
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • COVID-19對市場的影響分析

第4章 全身麻醉劑市場:各藥物類型

  • 概要
    • 市場規模與預測
  • PROPOFOL
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國
  • SEVOFLURANE
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國
  • DESFLURANE
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 其他
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國

第5章 全身麻醉劑市場:各給藥途徑

  • 概要
    • 市場規模與預測
  • 靜脈
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 吸入
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國

第6章 全身麻醉劑市場:各手術類型

  • 概要
    • 市場規模與預測
  • 膝關節、髖關節置換
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 心血管手術
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 癌症手術
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 一般外科手術
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國

第7章 全身麻醉劑市場:各終端用戶

  • 概要
    • 市場規模與預測
  • 醫院
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 門診病人手術中心
    • 主要的市場趨勢，成長要素與機會
    • 市場規模與預測:各地區
    • 市場分析:各國

第8章 全身麻醉劑市場:各地區

  • 概要
    • 市場規模與預測
  • 北美
  • 歐洲
  • 亞太地區
  • 南美、中東、非洲

第9章 企業形勢

  • 簡介
  • 主要的成功策略
  • 主要十大公司的產品製圖
  • 競爭儀表板
  • 競爭熱圖
  • 主要的發展

第10章 企業簡介

  • B. Braun Melsungen
  • Baxter International Inc.
  • Fresenius SE and Co. KGaA
  • Hikma Pharmaceuticals plc
  • Paion AG
  • Pfizer Inc.
  • Abbott Laboratories
  • Abbvie Inc.
  • AstraZeneca plc
  • Avet Pharmaceuticals Inc.
Product Code: A05262

The general anesthesia drug market was valued at $5,400.5 million in 2021, and is projected to reach $7,736.3 million by 2031, registering a CAGR of 3.5% from 2022 to 2031. General anesthesia is a combination of medication which causes sleep-like state before a surgery or other medical procedure. Under general anesthesia patient does not feel pain because patient is completely in unconscious state. General anesthesia is given with the combination of intravenous and inhalation anesthesia drugs. There are many equipment specifically designed for different surgical procedures. These include anesthetic vaporizer that is used as a vaporizing anesthetic; nasal oxygen set for delivering oxygen and others.  Some intravenous drugs such as propofol, etomidate, and ketamine are intravenous sedative hypotonic agents which are given in general anesthesia. Sevoflurane and desflurane are inhalation general anesthesia drugs which are used during surgical procedure.

The general anesthesia drug market is majorly driven by increase in number of surgical procedures like hip and knee replacement surgery, cardiac surgery, general surgeries cancer surgeries, rise in number of geriatric population, increase in prevalence of osteoarthritis disease, and neurological disorder. Moreover increase in number of key players to formulate general anesthesia drug, propels the growth of the market. According to the rheumatology advisor, the annual number of total knee arthroplasty was predicted to increase by 56% from 2019 to 2020. The demand for general anesthesia increases due to an increase in the number of knee arthroplasty surgery procedures. The knee and hip replacement procedures are majorly conducted under general anesthesia. Increase in prevalence of chronic disease, such as cardiovascular disease, cancer, and others is one of the major factor that boosts the growth of the market. According to the Centers for disease control and prevention (CDC) approximately 659,000 population in the U.S. experienced death from heart disease each year. According to the same report in 2019, a total of 360,900 people died due to coronary heart disease. Every year in the U.S. approximately 805,000 population are diagnosed with heart attack among which 605,000 experienced their first heart attack. This factor upsurges the need for heart surgery, which further increases the need for general anesthesia.

On the contrary, risk associated with general anesthesia such as allergic reaction, nausea, and vomiting is anticipated to hinder the market growth during the forecast period. Advancement in R&D activities in general anesthesia in pharmaceutical and biotechnology sector propels the growth of the market. Rise in funding from government or non-government organization to provide surgical resources, encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the general anesthesia drug market.

The general anesthesia drug market is segmented into type of drug, route of administration, surgery type, end user, and region. By type of drug, the market is categorized into propofol, sevoflurane, desflurane and other. Further the others segment is studied under ketamine, thiopental, methohexital, etomidate, isoflurane, and fospropofol. By route of administration, the market is bifurcated into intravenous and inhalation. By surgery, the market is divided into knee & hip replacements, heart surgeries, cancer surgery, and general surgery. By end user the market is classified into hospital and ambulatory surgical centers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the general anesthesia drug market are AbbVie, AstraZeneca, Avet Pharmaceuticals Inc. B. Braun Melsungen, Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, PAION AG, Abbott, and Pfizer.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the general anesthesia drugs market analysis from 2021 to 2031 to identify the prevailing general anesthesia drugs market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the general anesthesia drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global general anesthesia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By TYPE OF DRUGS

  • Propofol
  • Sevoflurane
  • Desflurane
  • Others

By ROUTE OF ADMNISTRATION

  • Intravenous
  • Inhalation

By SURGERY TYPE

  • Knee and hip replacements
  • Heart surgeries
  • Cancer surgery
  • General surgery

By END USER

  • Hospital
  • Ambulatory surgical centers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • B. Braun Melsungen
    • Baxter International Inc.
    • Fresenius SE and Co. KGaA
    • Hikma Pharmaceuticals plc
    • Paion AG
    • Pfizer Inc.
    • Abbott Laboratories
    • Abbvie Inc
    • AstraZeneca plc
    • Avet Pharmaceuticals Inc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Propofol
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Sevoflurane
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Desflurane
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Others
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Intravenous
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Inhalation
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Knee and hip replacements
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Heart surgeries
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Cancer surgery
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country
  • 6.5 General surgery
    • 6.5.1 Key market trends, growth factors and opportunities
    • 6.5.2 Market size and forecast, by region
    • 6.5.3 Market analysis by country

CHAPTER 7: GENERAL ANESTHESIA DRUGS MARKET, BY END USER

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Hospital
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market analysis by country
  • 7.3 Ambulatory surgical centers
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market analysis by country

CHAPTER 8: GENERAL ANESTHESIA DRUGS MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by TYPE OF DRUGS
    • 8.2.3 North America Market size and forecast, by ROUTE OF ADMNISTRATION
    • 8.2.4 North America Market size and forecast, by SURGERY TYPE
    • 8.2.5 North America Market size and forecast, by END USER
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Market size and forecast, by TYPE OF DRUGS
      • 8.2.6.1.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.2.6.1.3 Market size and forecast, by SURGERY TYPE
      • 8.2.6.1.4 Market size and forecast, by END USER
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Market size and forecast, by TYPE OF DRUGS
      • 8.2.6.2.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.2.6.2.3 Market size and forecast, by SURGERY TYPE
      • 8.2.6.2.4 Market size and forecast, by END USER
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Market size and forecast, by TYPE OF DRUGS
      • 8.2.6.3.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.2.6.3.3 Market size and forecast, by SURGERY TYPE
      • 8.2.6.3.4 Market size and forecast, by END USER
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by TYPE OF DRUGS
    • 8.3.3 Europe Market size and forecast, by ROUTE OF ADMNISTRATION
    • 8.3.4 Europe Market size and forecast, by SURGERY TYPE
    • 8.3.5 Europe Market size and forecast, by END USER
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Market size and forecast, by TYPE OF DRUGS
      • 8.3.6.1.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.3.6.1.3 Market size and forecast, by SURGERY TYPE
      • 8.3.6.1.4 Market size and forecast, by END USER
      • 8.3.6.2 France
      • 8.3.6.2.1 Market size and forecast, by TYPE OF DRUGS
      • 8.3.6.2.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.3.6.2.3 Market size and forecast, by SURGERY TYPE
      • 8.3.6.2.4 Market size and forecast, by END USER
      • 8.3.6.3 U.K.
      • 8.3.6.3.1 Market size and forecast, by TYPE OF DRUGS
      • 8.3.6.3.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.3.6.3.3 Market size and forecast, by SURGERY TYPE
      • 8.3.6.3.4 Market size and forecast, by END USER
      • 8.3.6.4 Italy
      • 8.3.6.4.1 Market size and forecast, by TYPE OF DRUGS
      • 8.3.6.4.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.3.6.4.3 Market size and forecast, by SURGERY TYPE
      • 8.3.6.4.4 Market size and forecast, by END USER
      • 8.3.6.5 Spain
      • 8.3.6.5.1 Market size and forecast, by TYPE OF DRUGS
      • 8.3.6.5.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.3.6.5.3 Market size and forecast, by SURGERY TYPE
      • 8.3.6.5.4 Market size and forecast, by END USER
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Market size and forecast, by TYPE OF DRUGS
      • 8.3.6.6.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.3.6.6.3 Market size and forecast, by SURGERY TYPE
      • 8.3.6.6.4 Market size and forecast, by END USER
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by TYPE OF DRUGS
    • 8.4.3 Asia-Pacific Market size and forecast, by ROUTE OF ADMNISTRATION
    • 8.4.4 Asia-Pacific Market size and forecast, by SURGERY TYPE
    • 8.4.5 Asia-Pacific Market size and forecast, by END USER
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 China
      • 8.4.6.1.1 Market size and forecast, by TYPE OF DRUGS
      • 8.4.6.1.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.4.6.1.3 Market size and forecast, by SURGERY TYPE
      • 8.4.6.1.4 Market size and forecast, by END USER
      • 8.4.6.2 Japan
      • 8.4.6.2.1 Market size and forecast, by TYPE OF DRUGS
      • 8.4.6.2.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.4.6.2.3 Market size and forecast, by SURGERY TYPE
      • 8.4.6.2.4 Market size and forecast, by END USER
      • 8.4.6.3 India
      • 8.4.6.3.1 Market size and forecast, by TYPE OF DRUGS
      • 8.4.6.3.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.4.6.3.3 Market size and forecast, by SURGERY TYPE
      • 8.4.6.3.4 Market size and forecast, by END USER
      • 8.4.6.4 Australia
      • 8.4.6.4.1 Market size and forecast, by TYPE OF DRUGS
      • 8.4.6.4.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.4.6.4.3 Market size and forecast, by SURGERY TYPE
      • 8.4.6.4.4 Market size and forecast, by END USER
      • 8.4.6.5 South Korea
      • 8.4.6.5.1 Market size and forecast, by TYPE OF DRUGS
      • 8.4.6.5.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.4.6.5.3 Market size and forecast, by SURGERY TYPE
      • 8.4.6.5.4 Market size and forecast, by END USER
      • 8.4.6.6 Rest of Asia-Pacific
      • 8.4.6.6.1 Market size and forecast, by TYPE OF DRUGS
      • 8.4.6.6.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.4.6.6.3 Market size and forecast, by SURGERY TYPE
      • 8.4.6.6.4 Market size and forecast, by END USER
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by TYPE OF DRUGS
    • 8.5.3 LAMEA Market size and forecast, by ROUTE OF ADMNISTRATION
    • 8.5.4 LAMEA Market size and forecast, by SURGERY TYPE
    • 8.5.5 LAMEA Market size and forecast, by END USER
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Market size and forecast, by TYPE OF DRUGS
      • 8.5.6.1.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.5.6.1.3 Market size and forecast, by SURGERY TYPE
      • 8.5.6.1.4 Market size and forecast, by END USER
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Market size and forecast, by TYPE OF DRUGS
      • 8.5.6.2.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.5.6.2.3 Market size and forecast, by SURGERY TYPE
      • 8.5.6.2.4 Market size and forecast, by END USER
      • 8.5.6.3 South Africa
      • 8.5.6.3.1 Market size and forecast, by TYPE OF DRUGS
      • 8.5.6.3.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.5.6.3.3 Market size and forecast, by SURGERY TYPE
      • 8.5.6.3.4 Market size and forecast, by END USER
      • 8.5.6.4 Rest of LAMEA
      • 8.5.6.4.1 Market size and forecast, by TYPE OF DRUGS
      • 8.5.6.4.2 Market size and forecast, by ROUTE OF ADMNISTRATION
      • 8.5.6.4.3 Market size and forecast, by SURGERY TYPE
      • 8.5.6.4.4 Market size and forecast, by END USER

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

  • 10.1 B. Braun Melsungen
    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments
  • 10.2 Baxter International Inc.
    • 10.2.1 Company overview
    • 10.2.2 Company snapshot
    • 10.2.3 Operating business segments
    • 10.2.4 Product portfolio
    • 10.2.5 Business performance
    • 10.2.6 Key strategic moves and developments
  • 10.3 Fresenius SE and Co. KGaA
    • 10.3.1 Company overview
    • 10.3.2 Company snapshot
    • 10.3.3 Operating business segments
    • 10.3.4 Product portfolio
    • 10.3.5 Business performance
    • 10.3.6 Key strategic moves and developments
  • 10.4 Hikma Pharmaceuticals plc
    • 10.4.1 Company overview
    • 10.4.2 Company snapshot
    • 10.4.3 Operating business segments
    • 10.4.4 Product portfolio
    • 10.4.5 Business performance
    • 10.4.6 Key strategic moves and developments
  • 10.5 Paion AG
    • 10.5.1 Company overview
    • 10.5.2 Company snapshot
    • 10.5.3 Operating business segments
    • 10.5.4 Product portfolio
    • 10.5.5 Business performance
    • 10.5.6 Key strategic moves and developments
  • 10.6 Pfizer Inc.
    • 10.6.1 Company overview
    • 10.6.2 Company snapshot
    • 10.6.3 Operating business segments
    • 10.6.4 Product portfolio
    • 10.6.5 Business performance
    • 10.6.6 Key strategic moves and developments
  • 10.7 Abbott Laboratories
    • 10.7.1 Company overview
    • 10.7.2 Company snapshot
    • 10.7.3 Operating business segments
    • 10.7.4 Product portfolio
    • 10.7.5 Business performance
    • 10.7.6 Key strategic moves and developments
  • 10.8 Abbvie Inc
    • 10.8.1 Company overview
    • 10.8.2 Company snapshot
    • 10.8.3 Operating business segments
    • 10.8.4 Product portfolio
    • 10.8.5 Business performance
    • 10.8.6 Key strategic moves and developments
  • 10.9 AstraZeneca plc
    • 10.9.1 Company overview
    • 10.9.2 Company snapshot
    • 10.9.3 Operating business segments
    • 10.9.4 Product portfolio
    • 10.9.5 Business performance
    • 10.9.6 Key strategic moves and developments
  • 10.10 Avet Pharmaceuticals Inc
    • 10.10.1 Company overview
    • 10.10.2 Company snapshot
    • 10.10.3 Operating business segments
    • 10.10.4 Product portfolio
    • 10.10.5 Business performance
    • 10.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 2. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR PROPOFOL, BY REGION , 2021-2031,($MILLION)
  • TABLE 3. GENERAL ANESTHESIA DRUGS MARKET FOR PROPOFOL BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 4. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR SEVOFLURANE, BY REGION , 2021-2031,($MILLION)
  • TABLE 5. GENERAL ANESTHESIA DRUGS MARKET FOR SEVOFLURANE BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 6. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR DESFLURANE, BY REGION , 2021-2031,($MILLION)
  • TABLE 7. GENERAL ANESTHESIA DRUGS MARKET FOR DESFLURANE BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 8. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2031,($MILLION)
  • TABLE 9. GENERAL ANESTHESIA DRUGS MARKET FOR OTHERS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 10. GLOBAL GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 11. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR INTRAVENOUS, BY REGION , 2021-2031,($MILLION)
  • TABLE 12. GENERAL ANESTHESIA DRUGS MARKET FOR INTRAVENOUS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 13. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR INHALATION, BY REGION , 2021-2031,($MILLION)
  • TABLE 14. GENERAL ANESTHESIA DRUGS MARKET FOR INHALATION BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 15. GLOBAL GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 16. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR KNEE AND HIP REPLACEMENTS, BY REGION , 2021-2031,($MILLION)
  • TABLE 17. GENERAL ANESTHESIA DRUGS MARKET FOR KNEE AND HIP REPLACEMENTS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 18. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR HEART SURGERIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 19. GENERAL ANESTHESIA DRUGS MARKET FOR HEART SURGERIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 20. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR CANCER SURGERY, BY REGION , 2021-2031,($MILLION)
  • TABLE 21. GENERAL ANESTHESIA DRUGS MARKET FOR CANCER SURGERY BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 22. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR GENERAL SURGERY, BY REGION , 2021-2031,($MILLION)
  • TABLE 23. GENERAL ANESTHESIA DRUGS MARKET FOR GENERAL SURGERY BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 24. GLOBAL GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 25. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR HOSPITAL, BY REGION , 2021-2031,($MILLION)
  • TABLE 26. GENERAL ANESTHESIA DRUGS MARKET FOR HOSPITAL BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 27. GENERAL ANESTHESIA DRUGS MARKET REVENUE, FOR AMBULATORY SURGICAL CENTERS, BY REGION , 2021-2031,($MILLION)
  • TABLE 28. GENERAL ANESTHESIA DRUGS MARKET FOR AMBULATORY SURGICAL CENTERS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 29. GENERAL ANESTHESIA DRUGS MARKET, BY REGION, 2021-2031,($MILLION)
  • TABLE 30. NORTH AMERICA GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 31. NORTH AMERICA GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 32. NORTH AMERICA GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 33. NORTH AMERICA GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 34. NORTH AMERICA GENERAL ANESTHESIA DRUGS MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 35. U.S. GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 36. U.S. GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 37. U.S. GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 38. U.S. GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 39. CANADA GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 40. CANADA GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 41. CANADA GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 42. CANADA GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 43. MEXICO GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 44. MEXICO GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 45. MEXICO GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 46. MEXICO GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 47. EUROPE GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 48. EUROPE GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 49. EUROPE GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 50. EUROPE GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 51. EUROPE GENERAL ANESTHESIA DRUGS MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 52. GERMANY GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 53. GERMANY GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 54. GERMANY GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 55. GERMANY GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 56. FRANCE GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 57. FRANCE GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 58. FRANCE GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 59. FRANCE GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 60. U.K. GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 61. U.K. GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 62. U.K. GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 63. U.K. GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 64. ITALY GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 65. ITALY GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 66. ITALY GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 67. ITALY GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 68. SPAIN GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 69. SPAIN GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 70. SPAIN GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 71. SPAIN GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 72. REST OF EUROPE GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 73. REST OF EUROPE GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 74. REST OF EUROPE GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 75. REST OF EUROPE GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 76. ASIA-PACIFIC GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 77. ASIA-PACIFIC GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 78. ASIA-PACIFIC GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 79. ASIA-PACIFIC GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 80. ASIA-PACIFIC GENERAL ANESTHESIA DRUGS MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 81. CHINA GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 82. CHINA GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 83. CHINA GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 84. CHINA GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 85. JAPAN GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 86. JAPAN GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 87. JAPAN GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 88. JAPAN GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 89. INDIA GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 90. INDIA GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 91. INDIA GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 92. INDIA GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 93. AUSTRALIA GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 94. AUSTRALIA GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 95. AUSTRALIA GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 96. AUSTRALIA GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 97. SOUTH KOREA GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 98. SOUTH KOREA GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 99. SOUTH KOREA GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 100. SOUTH KOREA GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 101. REST OF ASIA-PACIFIC GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 102. REST OF ASIA-PACIFIC GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 103. REST OF ASIA-PACIFIC GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 104. REST OF ASIA-PACIFIC GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 105. LAMEA GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 106. LAMEA GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 107. LAMEA GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 108. LAMEA GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 109. LAMEA GENERAL ANESTHESIA DRUGS MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 110. BRAZIL GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 111. BRAZIL GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 112. BRAZIL GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 113. BRAZIL GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 114. SAUDI ARABIA GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 115. SAUDI ARABIA GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 116. SAUDI ARABIA GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 117. SAUDI ARABIA GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 118. SOUTH AFRICA GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 119. SOUTH AFRICA GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 120. SOUTH AFRICA GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 121. SOUTH AFRICA GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 122. REST OF LAMEA GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS, 2021-2031,($MILLION)
  • TABLE 123. REST OF LAMEA GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION, 2021-2031,($MILLION)
  • TABLE 124. REST OF LAMEA GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE, 2021-2031,($MILLION)
  • TABLE 125. REST OF LAMEA GENERAL ANESTHESIA DRUGS MARKET, BY END USER, 2021-2031,($MILLION)
  • TABLE 126.B. BRAUN MELSUNGEN: COMPANY SNAPSHOT
  • TABLE 127.B. BRAUN MELSUNGEN: OPERATING SEGMENTS
  • TABLE 128.B. BRAUN MELSUNGEN: PRODUCT PORTFOLIO
  • TABLE 129.B. BRAUN MELSUNGEN: NET SALES,
  • TABLE 130.B. BRAUN MELSUNGEN: KEY STRATERGIES
  • TABLE 131.BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 132.BAXTER INTERNATIONAL INC.: OPERATING SEGMENTS
  • TABLE 133.BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 134.BAXTER INTERNATIONAL INC.: NET SALES,
  • TABLE 135.BAXTER INTERNATIONAL INC.: KEY STRATERGIES
  • TABLE 136.FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT
  • TABLE 137.FRESENIUS SE AND CO. KGAA: OPERATING SEGMENTS
  • TABLE 138.FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO
  • TABLE 139.FRESENIUS SE AND CO. KGAA: NET SALES,
  • TABLE 140.FRESENIUS SE AND CO. KGAA: KEY STRATERGIES
  • TABLE 141.HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
  • TABLE 142.HIKMA PHARMACEUTICALS PLC: OPERATING SEGMENTS
  • TABLE 143.HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
  • TABLE 144.HIKMA PHARMACEUTICALS PLC: NET SALES,
  • TABLE 145.HIKMA PHARMACEUTICALS PLC: KEY STRATERGIES
  • TABLE 146.PAION AG: COMPANY SNAPSHOT
  • TABLE 147.PAION AG: OPERATING SEGMENTS
  • TABLE 148.PAION AG: PRODUCT PORTFOLIO
  • TABLE 149.PAION AG: NET SALES,
  • TABLE 150.PAION AG: KEY STRATERGIES
  • TABLE 151.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 152.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 153.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 154.PFIZER INC.: NET SALES,
  • TABLE 155.PFIZER INC.: KEY STRATERGIES
  • TABLE 156.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 157.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 158.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 159.ABBOTT LABORATORIES: NET SALES,
  • TABLE 160.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 161.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 162.ABBVIE INC: OPERATING SEGMENTS
  • TABLE 163.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 164.ABBVIE INC: NET SALES,
  • TABLE 165.ABBVIE INC: KEY STRATERGIES
  • TABLE 166.ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 167.ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 168.ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 169.ASTRAZENECA PLC: NET SALES,
  • TABLE 170.ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 171.AVET PHARMACEUTICALS INC: COMPANY SNAPSHOT
  • TABLE 172.AVET PHARMACEUTICALS INC: OPERATING SEGMENTS
  • TABLE 173.AVET PHARMACEUTICALS INC: PRODUCT PORTFOLIO
  • TABLE 174.AVET PHARMACEUTICALS INC: NET SALES,
  • TABLE 175.AVET PHARMACEUTICALS INC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.GENERAL ANESTHESIA DRUGS MARKET SEGMENTATION
  • FIGURE 2.GENERAL ANESTHESIA DRUGS MARKET,2021-2031
  • FIGURE 3.GENERAL ANESTHESIA DRUGS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.GENERAL ANESTHESIA DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.GENERAL ANESTHESIA DRUGS MARKET,BY TYPE OF DRUGS,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF PROPOFOL GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SEVOFLURANE GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF DESFLURANE GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 17.GENERAL ANESTHESIA DRUGS MARKET,BY ROUTE OF ADMNISTRATION,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF INTRAVENOUS GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF INHALATION GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 20.GENERAL ANESTHESIA DRUGS MARKET,BY SURGERY TYPE,2021(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF KNEE AND HIP REPLACEMENTS GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HEART SURGERIES GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CANCER SURGERY GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF GENERAL SURGERY GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 25.GENERAL ANESTHESIA DRUGS MARKET,BY END USER,2021(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF HOSPITAL GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF AMBULATORY SURGICAL CENTERS GENERAL ANESTHESIA DRUGS MARKET,2021-2031(%)
  • FIGURE 28.GENERAL ANESTHESIA DRUGS MARKET BY REGION,2021
  • FIGURE 29.U.S. GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 30.CANADA GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 31.MEXICO GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 32.GERMANY GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 33.FRANCE GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 34.U.K. GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 35.ITALY GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 36.SPAIN GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 37.REST OF EUROPE GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 38.CHINA GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 39.JAPAN GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 40.INDIA GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 41.AUSTRALIA GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 42.SOUTH KOREA GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF ASIA-PACIFIC GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 44.BRAZIL GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 45.SAUDI ARABIA GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 46.SOUTH AFRICA GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 47.REST OF LAMEA GENERAL ANESTHESIA DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52.COMPETITIVE DASHBOARD
  • FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 54.B. BRAUN MELSUNGEN.: NET SALES ,($MILLION)
  • FIGURE 55.BAXTER INTERNATIONAL INC..: NET SALES ,($MILLION)
  • FIGURE 56.FRESENIUS SE AND CO. KGAA.: NET SALES ,($MILLION)
  • FIGURE 57.HIKMA PHARMACEUTICALS PLC.: NET SALES ,($MILLION)
  • FIGURE 58.PAION AG.: NET SALES ,($MILLION)
  • FIGURE 59.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 60.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
  • FIGURE 61.ABBVIE INC.: NET SALES ,($MILLION)
  • FIGURE 62.ASTRAZENECA PLC.: NET SALES ,($MILLION)
  • FIGURE 63.AVET PHARMACEUTICALS INC.: NET SALES ,($MILLION)